UQ’s Diamantina Institute Ranjeny Thomas.
Human trials of an innovative treatment for rheumatoid arthritis developed by The University of Queensland have begun in Brisbane. DEN-181, a vaccine-style treatment referred to as an 'immunotherapy', targets the underlying cause of the disease rather than treating its inflammatory symptoms. Patient trials at a clinical research facility at the Princess Alexandra Hospital began last week. UQ's Diamantina Institute research team, led by Professor Ranjeny Thomas , discovered the body's immune system could be 're-educated' to turn off, rather than react to a self-antigen responsible for autoimmune disease like rheumatoid arthritis. This led to the development of DEN-181. DEN-181 is being commercialised by Dendright Pty Ltd , a start-up company of UniQuest , UQ's commercialisation company. UniQuest CEO Dr Dean Moss said the first-in-human trial was a momentous step towards making the breakthrough research discovery a treatment reality.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
